Is the small non-cleaved-cell lymphoma histologic subtype a poor prognostic factor in adult patients? A case-controlled analysis

被引:18
作者
Divine, M
Lepage, E
Briere, J
Pautier, P
Dupriez, B
Lederlin, P
Mineur, P
Tilly, H
Blanc, M
Audhuy, B
Herbrecht, R
Coiffier, B
Reyes, F
机构
[1] HOP ST LOUIS,PARIS,FRANCE
[2] HOP LAENNEC,F-75340 PARIS,FRANCE
[3] HOP HAUTE PIERRE,STRASBOURG,FRANCE
[4] CTR HOSP SCHAFFNER,LENS,FRANCE
[5] CTR HOSP SCHAFFNER,LENS,FRANCE
[6] CTR HENRI BECQUEREL,F-76038 ROUEN,FRANCE
[7] HOP LOUIS PASTEUR,COLMAR,FRANCE
[8] CTR HOSP LYON SUD,F-69310 PIERRE BENITE,FRANCE
[9] HOP ST JOSEPH,GILLY,BELGIUM
关键词
D O I
10.1200/JCO.1996.14.1.240
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To study the prognostic significance of the small non-cleaved-cell lymphoma (SNCCL) histologic subtype, we compared the outcome of adult patients with SNCCL with that of patients with aggressive lymphoma other than SNCCL by means of two case-controlled studies. Patients and Methods: We analyzed the results of the doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone (ACVBP) regimen used as a reference scheme in our cooperative study group (Groupe d'Etude des Lymphomes de l'Adult [GELA]) in 52 adult SNCCL patients with no bone marrow (BM) or CNS involvement. Forty-five SNCCL patients younger than 60 years could be compared with two separate case-matched groups of patients with aggressive lymphoma other than SNCCL undergoing the same therapeutic regimen, In the first case-controlled study, matching ensured identity of each risk factor of the age-adjusted international Index (ie, Ann Arbor stage, performance status, and lactate dehydrogenase [LDH] level); in the second study, matching was performed according to the number of presenting risk factors (zero, one, two, or three), regardless of their nature. Results: The 5-year overall survival rates were not significantly different between SNCCL and control patients in both case-controlled studies: 48% versus 51% in the first study, and 48% versus 55% in the second study. Conclusion: These results support the thesis that in patients with no bone marrow or CNS involvement, the SNCCL histologic subtype does not confer a prognosis worse than that of other aggressive lymphoma. (C) 1996 by American Society of Clinical Oncology.
引用
收藏
页码:240 / 248
页数:9
相关论文
共 30 条
[11]  
LEVINE AM, 1983, CANCER, V52, P1073, DOI 10.1002/1097-0142(19830915)52:6<1073::AID-CNCR2820520624>3.0.CO
[12]  
2-F
[13]   AMERICAN-BURKITT-LYMPHOMA-REGISTRY - PROGRESS REPORT [J].
LEVINE, PH ;
CHO, BR ;
CONNELLY, RR ;
BERARD, CW ;
OCONOR, GT ;
DORFMAN, RF ;
EASTON, JM ;
DEVITA, VT .
ANNALS OF INTERNAL MEDICINE, 1975, 83 (01) :31-36
[14]   DIFFUSE SMALL NONCLEAVED-CELL, NON-BURKITTS LYMPHOMA IN ADULTS - A HIGH-GRADE LYMPHOMA RESPONSIVE TO PROMACE-BASED COMBINATION CHEMOTHERAPY [J].
LONGO, DL ;
DUFFEY, PL ;
JAFFE, ES ;
RAFFELD, M ;
HUBBARD, SM ;
FISHER, RI ;
WITTES, RE ;
DEVITA, VT ;
YOUNG, RC .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (10) :2153-2159
[15]   SMALL NONCLEAVED CELL LYMPHOMA IN ADULTS - SUPERIOR RESULTS FOR STAGES-I-III DISEASE [J].
LOPEZ, TM ;
HAGEMEISTER, FB ;
MCLAUGHLIN, P ;
VELASQUEZ, WS ;
SWAN, F ;
REDMAN, JR ;
RODRIGUEZ, MA ;
TUCKER, SL ;
SILVERMINTZ, K ;
JOHNSON, J ;
CABANILLAS, F .
JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (04) :615-622
[16]  
MAGRATH I, 1980, CANCER, V45, P1507, DOI 10.1002/1097-0142(19800315)45:6<1507::AID-CNCR2820450634>3.0.CO
[17]  
2-D
[18]  
MAGRATH IT, 1984, BLOOD, V63, P1102
[19]   EFFECTIVE TREATMENT OF SMALL-NONCLEAVED-CELL LYMPHOMA WITH HIGH-INTENSITY, BRIEF-DURATION CHEMOTHERAPY [J].
MCMASTER, ML ;
GREER, JP ;
GRECO, FA ;
JOHNSON, DH ;
WOLFF, SN ;
HAINSWORTH, JD .
JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (06) :941-946
[20]  
MILIAUSKAS JR, 1983, CANCER, V50, P2115